Jeffrey Schlom

72PUBLICATIONS
171CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (72)

|Oct 23, 2026
Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.

|Sep 12, 2026
Epigenetic plus cytokine therapy induces stem-like CD8+ T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance.

|Jul 24, 2026
Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.

|Apr 22, 2026
Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer.

|Mar 25, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Chennan Li, Ravi A Madan, Min-Jung Lee

|Dec 19, 2025
The ATR inhibitor tuvusertib (M1774) sensitizes prostate carcinoma to natural killer cell-mediated cytotoxicity, which is further augmented by the IL-15 receptor superagonist N-803.

Cailyn A Lee, Jeffrey Schlom, James W Hodge

Pageof 12

Frequent Collaborators

27 joint publications

James L Gulley

19 joint publications

Renee N Donahue

15 joint publications

Sofia R Gameiro

14 joint publications

Caroline Jochems